早期与平均发作的胆道癌症相比,具有治疗影响的分子差异
Thejus Jayakrishnan1,2, Yasmine Baca3, Joanne Xiu3
1Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
JCO precision oncology
|August 5, 2024
概括
早期发病的胆道癌 (eoBTC) 与平均发病的BTC相比,显示出明显的分子特征,包括更高的FGFR2融合. 这些分子差异,特别是FGFR2融合状态,影响了患者的治疗结果,突出了先进基因组测试的必要性.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 癌症生物学 癌症生物学
背景情况:
- 早期发病的癌症,包括胆道癌 (BTC),是越来越令人担忧的,对其潜在生物学知识的理解有限.
- 区分早期BTC (eoBTC) 和平均发病BTC (aoBTC) 之间的分子特征对于向治疗至关重要.
研究的目的:
- 通过使用全面的多组学数据集,识别eobtc和aobtc之间的新分子差异.
- 调查这些分子差异对患者结果的影响.
主要方法:
- 追溯分析了5587名BTC患者 (453人BTC,5134人BTC) 的分子分析数据.
- 在eoBTC和aoBTC组之间比较分子变化,包括基因融合和免疫评分.
- 使用保险索赔数据进行生存分析,以将分子特征与整体存活率 (OS) 相关联.
主要成果:
- 与aoBTC相比,eoBTC中FGFR2融合 (15.7%与5.9%) 和NIPBL融合 (1.1%与0%) 的流行率明显更高.
- eoBTC显示在血管生成途径中的丰富,而aoBTC显示在干扰素玛和炎症反应途径中的丰富.
- 在eoBTC (16.5个月) 和aoBTC (13.3个月) 中,总生存时间更长,FGFR2融合状态影响了两组的结果.
结论:
- eoBTC和aoBTC之间存在显著的分子差异,特别是年轻患者FGFR2融合的频率增加.
- FGFR2融合状态是eoBTC结果的关键决定因素,强调其作为治疗目标的重要性.
- 调查结果强调,需要广泛使用下一代测序来早期识别BTC中可操作的目标.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K